Dr. Mauro Discusses Drug Adherence Among CML Patients
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don’t adhere to their medication.
Mauro says once the disease has been treated, there are minimal symptoms. However, the therapies used to treat CML can lead to chronic low-grade adverse events. Since CML treatment is indefinite, this can be challenging for patients to deal with, Mauro says.​
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
